Brief: FDA Issues “Safe To Proceed” Letter To Initiate EAP For Revolution Medicines' Daraxonrasib
01/05/2026 18:13
May 1 (Reuters) - Revolution Medicines Inc RVMD.O: REVOLUTION MEDICINES: FDA ISSUED “SAFE TO PROCEED” LETTER TO INITIATE EXPANDED ACCESS TREATMENT PROTOCOL FOR DARAXONRASIB FOR PANCREATIC CANCER ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revolution Medicines
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
Brief: CHMP Recommends Granting Marketing Authorisation For Rasonque For Metastatic Pancreatic Cancer In EU
Revolution Medicines wins EU committee backing for pancreatic cancer treatment (updated)
EMA recommends approval of Revolution's pancreatic cancer drug
Revolution Medicines falls on pancreatic cancer drug data concerns